Skip to main content
Top
Published in: Health and Quality of Life Outcomes 1/2023

Open Access 01-12-2023 | Ulcerative Colitis | Research

Implementing electronic patient reported outcomes in inflammatory bowel disease: patient participation, score reliability and validity

Authors: Daniel Deutscher, Clara Weil, Gabriel Chodick, Sveta Tsukinovsky, Keith Bodger, Matti Waterman, Revital Kariv

Published in: Health and Quality of Life Outcomes | Issue 1/2023

Login to get access

Abstract

Background

Patient-reported outcome measures (PROMs) are recommended for assessing patient-centered outcomes in inflammatory bowel disease (IBD). The main aims were to assess the level of participation in an electronic PROM (ePROM) data collection system among patients with IBD, and evaluate reliability and validity of the resulting scores.

Methods

Patients included in the IBD registry of Maccabi Healthcare Services, a state-mandated healthcare provider for over 2.6 million people in Israel, were invited to complete the IBD-Control measure and a general health item, with follow-up ePROMs at 3 and 6 months including a global rating of change item. Descriptive statistics were used to compare patient characteristics by participation rate, and assess survey completion time. Initial scores were assessed for internal consistency reliability using Cronbach's alpha. Test–retest reliability was assessed using the intraclass correlation coefficient from paired scores of patients identified as unchanged between the initial and first follow-up. Construct validity was assessed by the ability of IBD-control scores to discriminate between patient sub-groups in expected ways. Empirical validity was assessed using ePROM score correlations with laboratory markers of disease activity. Score coverage was also assessed.

Results

A total of 13,588 patients were invited to participate [Mean age = 49 years (SD = 17); females = 51%]. Participation rate was 31.5%. Participants compared to non-participants were slightly older, were more likely to be female, to have a history of biologic treatment, to have higher socio-economic status, and to be more experienced in the usage of the digital patient portal. Median survey completion time was approximately 1:30 min. Internal consistency and test–retest reliability were 0.86 and 0.98, respectively. Scores discriminated between patient sub-groups in clinically expected ways, with expected correlations to laboratory markers of disease activity. A notable ceiling effect was observed (> 15%) for IBD-Control scores.

Conclusions

Feasibility, reliability, and validity of the ePROM system was supported for measuring the level of perceived disease control in patients diagnosed with IBD in Israel. Additional research is needed to identify ways to increase patient participation, assess clinical implications of the identified measurement ceiling of the IBD-control, and evaluate the added value of the derived scores in support of clinical decision making.
Literature
1.
go back to reference Bingham CO 3rd, Noonan VK, Auger C, Feldman DE, Ahmed S, Bartlett SJ. Montreal Accord on Patient-Reported Outcomes (PROs) use series—Paper 4: patient-reported outcomes can inform clinical decision making in chronic care. J Clin Epidemiol. 2017;89:136–41.CrossRef Bingham CO 3rd, Noonan VK, Auger C, Feldman DE, Ahmed S, Bartlett SJ. Montreal Accord on Patient-Reported Outcomes (PROs) use series—Paper 4: patient-reported outcomes can inform clinical decision making in chronic care. J Clin Epidemiol. 2017;89:136–41.CrossRef
2.
go back to reference Porter I, Goncalves-Bradley D, Ricci-Cabello I, Gibbons C, Gangannagaripalli J, Fitzpatrick R, et al. Framework and guidance for implementing patient-reported outcomes in clinical practice: evidence, challenges and opportunities. J Comp Eff Res. 2016;5(5):507–19.CrossRef Porter I, Goncalves-Bradley D, Ricci-Cabello I, Gibbons C, Gangannagaripalli J, Fitzpatrick R, et al. Framework and guidance for implementing patient-reported outcomes in clinical practice: evidence, challenges and opportunities. J Comp Eff Res. 2016;5(5):507–19.CrossRef
3.
go back to reference Bojic D, Bodger K, Travis S. Patient Reported Outcome Measures (PROMs) in inflammatory bowel disease: new data. J Crohns Colitis. 2017;11(suppl_2):S576–S85. Bojic D, Bodger K, Travis S. Patient Reported Outcome Measures (PROMs) in inflammatory bowel disease: new data. J Crohns Colitis. 2017;11(suppl_2):S576–S85.
4.
go back to reference de Jong ME, Taal E, Thomas PWA, Romkens TEH, Jansen JM, West RL, et al. Cross-cultural translation and validation of the IBD-control questionnaire in The Netherlands: a patient-reported outcome measure in inflammatory bowel disease. Scand J Gastroenterol. 2021;56(2):155–61.CrossRef de Jong ME, Taal E, Thomas PWA, Romkens TEH, Jansen JM, West RL, et al. Cross-cultural translation and validation of the IBD-control questionnaire in The Netherlands: a patient-reported outcome measure in inflammatory bowel disease. Scand J Gastroenterol. 2021;56(2):155–61.CrossRef
5.
go back to reference de Jong MJ, Huibregtse R, Masclee AAM, Jonkers D, Pierik MJ. Patient-reported outcome measures for use in clinical trials and clinical practice in inflammatory bowel diseases: a systematic review. Clin Gastroenterol Hepatol. 2018;16(5):648–63 e3. de Jong MJ, Huibregtse R, Masclee AAM, Jonkers D, Pierik MJ. Patient-reported outcome measures for use in clinical trials and clinical practice in inflammatory bowel diseases: a systematic review. Clin Gastroenterol Hepatol. 2018;16(5):648–63 e3.
6.
go back to reference Bodger K, Ormerod C, Shackcloth D, Harrison M, Collaborative IBDC. Development and validation of a rapid, generic measure of disease control from the patient’s perspective: the IBD-control questionnaire. Gut. 2014;63(7):1092–102.CrossRef Bodger K, Ormerod C, Shackcloth D, Harrison M, Collaborative IBDC. Development and validation of a rapid, generic measure of disease control from the patient’s perspective: the IBD-control questionnaire. Gut. 2014;63(7):1092–102.CrossRef
7.
go back to reference Cheung WY, Garratt AM, Russell IT, Williams JG. The UK IBDQ-a British version of the inflammatory bowel disease questionnaire. development and validation. J Clin Epidemiol 2000;53(3):297–306. Cheung WY, Garratt AM, Russell IT, Williams JG. The UK IBDQ-a British version of the inflammatory bowel disease questionnaire. development and validation. J Clin Epidemiol 2000;53(3):297–306.
8.
go back to reference EuroQol G. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy (Amsterdam, Netherlands). 1990;16(3):199–208.CrossRef EuroQol G. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy (Amsterdam, Netherlands). 1990;16(3):199–208.CrossRef
9.
go back to reference Kim AH, Roberts C, Feagan BG, Banerjee R, Bemelman W, Bodger K, et al. Developing a Standard Set of Patient-Centred Outcomes for Inflammatory Bowel Disease-an International, Cross-disciplinary consensus. J Crohns Colitis. 2018;12(4):408–18.CrossRef Kim AH, Roberts C, Feagan BG, Banerjee R, Bemelman W, Bodger K, et al. Developing a Standard Set of Patient-Centred Outcomes for Inflammatory Bowel Disease-an International, Cross-disciplinary consensus. J Crohns Colitis. 2018;12(4):408–18.CrossRef
10.
go back to reference O’Connell S, Palmer R, Withers K, Saha N, Puntoni S, Carolan-Rees G, et al. Requirements for the collection of electronic PROMS either “in clinic” or “at home” as part of the PROMs, PREMs and Effectiveness Programme (PPEP) in Wales: a feasibility study using a generic PROM tool. Pilot Feasibility Stud. 2018;4:90.CrossRef O’Connell S, Palmer R, Withers K, Saha N, Puntoni S, Carolan-Rees G, et al. Requirements for the collection of electronic PROMS either “in clinic” or “at home” as part of the PROMs, PREMs and Effectiveness Programme (PPEP) in Wales: a feasibility study using a generic PROM tool. Pilot Feasibility Stud. 2018;4:90.CrossRef
11.
go back to reference Friedman MY, Leventer-Roberts M, Rosenblum J, Zigman N, Goren I, Mourad V, et al. Development and validation of novel algorithms to identify patients with inflammatory bowel diseases in Israel: an epi-IIRN group study. Clin Epidemiol. 2018;10:671–81.CrossRef Friedman MY, Leventer-Roberts M, Rosenblum J, Zigman N, Goren I, Mourad V, et al. Development and validation of novel algorithms to identify patients with inflammatory bowel diseases in Israel: an epi-IIRN group study. Clin Epidemiol. 2018;10:671–81.CrossRef
12.
go back to reference Kariv R, Turner D, Rosenblum J, Morad V, Zigman N, Friedman M, et al. Establishing a registry for inflammatory bowel disease patients in maccabi healthcare services—joint project between hospitals, Epi-Iirn Group and Community Medicine. Harefuah. 2018;157(10):655–9. Kariv R, Turner D, Rosenblum J, Morad V, Zigman N, Friedman M, et al. Establishing a registry for inflammatory bowel disease patients in maccabi healthcare services—joint project between hospitals, Epi-Iirn Group and Community Medicine. Harefuah. 2018;157(10):655–9.
13.
go back to reference Ludvigsson JF, Andersson M, Bengtsson J, Eberhardson M, Fagerberg UL, Grip O, et al. Swedish Inflammatory Bowel Disease Register (SWIBREG)—a nationwide quality register. Scand J Gastroenterol. 2019;54(9):1089–101.CrossRef Ludvigsson JF, Andersson M, Bengtsson J, Eberhardson M, Fagerberg UL, Grip O, et al. Swedish Inflammatory Bowel Disease Register (SWIBREG)—a nationwide quality register. Scand J Gastroenterol. 2019;54(9):1089–101.CrossRef
14.
go back to reference Hays RD, Bjorner JB, Revicki DA, Spritzer KL, Cella D. Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items. Qual Life Res. 2009;18(7):873–80.CrossRef Hays RD, Bjorner JB, Revicki DA, Spritzer KL, Cella D. Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items. Qual Life Res. 2009;18(7):873–80.CrossRef
15.
go back to reference Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10(4):407–15. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10(4):407–15.
16.
go back to reference Eremenco SL, Cella D, Arnold BJ. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Eval Health Prof. 2005;28(2):212–32.CrossRef Eremenco SL, Cella D, Arnold BJ. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Eval Health Prof. 2005;28(2):212–32.CrossRef
17.
go back to reference Israel Central Bureau of Statistics. Characterization and classification of geographic units by the socioeconomic level of the population 2008. Publication No. 1530. Jerusalem, Israel; 2013. Israel Central Bureau of Statistics. Characterization and classification of geographic units by the socioeconomic level of the population 2008. Publication No. 1530. Jerusalem, Israel; 2013.
18.
go back to reference Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083–107.CrossRef Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083–107.CrossRef
19.
go back to reference Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, N.J.: L. Erlbaum Associates; 1988. xxi, 567 p. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, N.J.: L. Erlbaum Associates; 1988. xxi, 567 p.
20.
go back to reference Stratford PW. Getting more from the literature: Estimating the standard error of measurement from reliability studies. Physiother Can. 2004;56:27–30.CrossRef Stratford PW. Getting more from the literature: Estimating the standard error of measurement from reliability studies. Physiother Can. 2004;56:27–30.CrossRef
21.
go back to reference Riddle DL, Stratford PW. Is this change real? Interpreting patient outcomes in physical therapy. Philadelphia: F.A. Davis Co.; 2013. Riddle DL, Stratford PW. Is this change real? Interpreting patient outcomes in physical therapy. Philadelphia: F.A. Davis Co.; 2013.
22.
go back to reference Deutscher D, Cook KF, Kallen MA, Werneke MW, Hayes D, Mioduski JE, et al. Clinical interpretation of the neck functional status computerized adaptive test. J Orthop Sports Phys Ther. 2019;49(12):875–86.CrossRef Deutscher D, Cook KF, Kallen MA, Werneke MW, Hayes D, Mioduski JE, et al. Clinical interpretation of the neck functional status computerized adaptive test. J Orthop Sports Phys Ther. 2019;49(12):875–86.CrossRef
23.
go back to reference Schober P, Boer C, Schwarte LA. Correlation coefficients: appropriate use and interpretation. Anesth Analg. 2018;126(5):1763–8.CrossRef Schober P, Boer C, Schwarte LA. Correlation coefficients: appropriate use and interpretation. Anesth Analg. 2018;126(5):1763–8.CrossRef
24.
go back to reference Bathe AL, Mavropoulou E, Mechie NC, Petzold G, Ellenrieder V, Kunsch S, et al. Impact of faecal calprotectin measurement on clinical decision-making in patients with Crohn’s disease and ulcerative colitis. PLoS ONE. 2019;14(10): e0223893.CrossRef Bathe AL, Mavropoulou E, Mechie NC, Petzold G, Ellenrieder V, Kunsch S, et al. Impact of faecal calprotectin measurement on clinical decision-making in patients with Crohn’s disease and ulcerative colitis. PLoS ONE. 2019;14(10): e0223893.CrossRef
25.
go back to reference Blumenstein I, Herrmann E, Filmann N, Zosel C, Tacke W, Bock H, et al. Female patients suffering from inflammatory bowel diseases are treated less frequently with immunosuppressive medication and have a higher disease activity: a subgroup analysis of a large multi-centre, prospective, internet-based study. J Crohns Colitis. 2011;5(3):203–10.CrossRef Blumenstein I, Herrmann E, Filmann N, Zosel C, Tacke W, Bock H, et al. Female patients suffering from inflammatory bowel diseases are treated less frequently with immunosuppressive medication and have a higher disease activity: a subgroup analysis of a large multi-centre, prospective, internet-based study. J Crohns Colitis. 2011;5(3):203–10.CrossRef
26.
go back to reference Chen G, Lissoos T, Dieyi C, Null KD. Development and validation of an inflammatory bowel disease severity index using US administrative claims data: a retrospective cohort study. Inflamm Bowel Dis. 2021;27(8):1177–83.CrossRef Chen G, Lissoos T, Dieyi C, Null KD. Development and validation of an inflammatory bowel disease severity index using US administrative claims data: a retrospective cohort study. Inflamm Bowel Dis. 2021;27(8):1177–83.CrossRef
27.
go back to reference Greuter T, Manser C, Pittet V, Vavricka SR, Biedermann L, on behalf of Swiss Ibdnet aowgotSSoG. Gender differences in inflammatory bowel disease. digestion. 2020;101 Suppl 1:98–104. Greuter T, Manser C, Pittet V, Vavricka SR, Biedermann L, on behalf of Swiss Ibdnet aowgotSSoG. Gender differences in inflammatory bowel disease. digestion. 2020;101 Suppl 1:98–104.
28.
go back to reference Park KT, Ehrlich OG, Allen JI, Meadows P, Szigethy EM, Henrichsen K, et al. The cost of inflammatory bowel disease: an initiative from the Crohn’s & Colitis Foundation. Inflamm Bowel Dis. 2020;26(1):1–10.CrossRef Park KT, Ehrlich OG, Allen JI, Meadows P, Szigethy EM, Henrichsen K, et al. The cost of inflammatory bowel disease: an initiative from the Crohn’s & Colitis Foundation. Inflamm Bowel Dis. 2020;26(1):1–10.CrossRef
29.
go back to reference Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J, et al. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol. 2007;60(1):34–42.CrossRef Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J, et al. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol. 2007;60(1):34–42.CrossRef
30.
go back to reference Wamper KE, Sierevelt IN, Poolman RW, Bhandari M, Haverkamp D. The Harris hip score: Do ceiling effects limit its usefulness in orthopedics? Acta Orthop. 2010;81(6):703–7.CrossRef Wamper KE, Sierevelt IN, Poolman RW, Bhandari M, Haverkamp D. The Harris hip score: Do ceiling effects limit its usefulness in orthopedics? Acta Orthop. 2010;81(6):703–7.CrossRef
31.
go back to reference IBM Corp. Released 2017. IBM SPSS Statistics for Windows, Version 25.0. Version 25.0 ed. Armonk, NY: IBM Corp. IBM Corp. Released 2017. IBM SPSS Statistics for Windows, Version 25.0. Version 25.0 ed. Armonk, NY: IBM Corp.
32.
go back to reference StataCorp. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP2015. StataCorp. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP2015.
33.
go back to reference Borowsky PA, Kadri OM, Meldau JE, Blanchett J, Makhni EC. The Remote Completion Rate of Electronic Patient-Reported Outcome Forms Before Scheduled Clinic Visits-A Proof-of-Concept Study Using Patient-Reported Outcome Measurement Information System Computer Adaptive Test Questionnaires. J Am Acad Orthop Surg Glob Res Rev. 2019;3(10). Borowsky PA, Kadri OM, Meldau JE, Blanchett J, Makhni EC. The Remote Completion Rate of Electronic Patient-Reported Outcome Forms Before Scheduled Clinic Visits-A Proof-of-Concept Study Using Patient-Reported Outcome Measurement Information System Computer Adaptive Test Questionnaires. J Am Acad Orthop Surg Glob Res Rev. 2019;3(10).
34.
go back to reference Howard JS, Toonstra JL, Meade AR, Whale Conley CE, Mattacola CG. Feasibility of conducting a web-based survey of patient-reported outcomes and rehabilitation progress. Digit Health. 2016;2:2055207616644844. Howard JS, Toonstra JL, Meade AR, Whale Conley CE, Mattacola CG. Feasibility of conducting a web-based survey of patient-reported outcomes and rehabilitation progress. Digit Health. 2016;2:2055207616644844.
35.
go back to reference Licqurish SM, Cook OY, Pattuwage LP, Saunders C, Jefford M, Koczwara B, et al. Tools to facilitate communication during physician-patient consultations in cancer care: an overview of systematic reviews. CA Cancer J Clin. 2019;69(6):497–520.CrossRef Licqurish SM, Cook OY, Pattuwage LP, Saunders C, Jefford M, Koczwara B, et al. Tools to facilitate communication during physician-patient consultations in cancer care: an overview of systematic reviews. CA Cancer J Clin. 2019;69(6):497–520.CrossRef
36.
go back to reference Karsten MM, Speiser D, Hartmann C, Zeuschner N, Lippold K, Kiver V, et al. Web-based patient-reported outcomes using the international consortium for health outcome measurement dataset in a major German University Hospital: observational study. JMIR Cancer. 2018;4(2): e11373.CrossRef Karsten MM, Speiser D, Hartmann C, Zeuschner N, Lippold K, Kiver V, et al. Web-based patient-reported outcomes using the international consortium for health outcome measurement dataset in a major German University Hospital: observational study. JMIR Cancer. 2018;4(2): e11373.CrossRef
37.
go back to reference Millar MM, Elena JW, Gallicchio L, Edwards SL, Carter ME, Herget KA, et al. The feasibility of web surveys for obtaining patient-reported outcomes from cancer survivors: a randomized experiment comparing survey modes and brochure enclosures. BMC Med Res Methodol. 2019;19(1):208.CrossRef Millar MM, Elena JW, Gallicchio L, Edwards SL, Carter ME, Herget KA, et al. The feasibility of web surveys for obtaining patient-reported outcomes from cancer survivors: a randomized experiment comparing survey modes and brochure enclosures. BMC Med Res Methodol. 2019;19(1):208.CrossRef
38.
go back to reference Mosli MH, Zou G, Garg SK, Feagan SG, MacDonald JK, Chande N, et al. C-Reactive Protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis. Am J Gastroenterol. 2015;110(6):802–20.CrossRef Mosli MH, Zou G, Garg SK, Feagan SG, MacDonald JK, Chande N, et al. C-Reactive Protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis. Am J Gastroenterol. 2015;110(6):802–20.CrossRef
39.
go back to reference Burisch J, Zammit SC, Ellul P, Turcan S, Duricova D, Bortlik M, et al. Disease course of inflammatory bowel disease unclassified in a European population-based inception cohort: an Epi-IBD study. J Gastroenterol Hepatol. 2019;34(6):996–1003.CrossRef Burisch J, Zammit SC, Ellul P, Turcan S, Duricova D, Bortlik M, et al. Disease course of inflammatory bowel disease unclassified in a European population-based inception cohort: an Epi-IBD study. J Gastroenterol Hepatol. 2019;34(6):996–1003.CrossRef
Metadata
Title
Implementing electronic patient reported outcomes in inflammatory bowel disease: patient participation, score reliability and validity
Authors
Daniel Deutscher
Clara Weil
Gabriel Chodick
Sveta Tsukinovsky
Keith Bodger
Matti Waterman
Revital Kariv
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2023
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/s12955-023-02087-0

Other articles of this Issue 1/2023

Health and Quality of Life Outcomes 1/2023 Go to the issue